Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position
https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel
Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
0
Healthcare dealmakers see increased M&A, valuations in 2024: KPMG
https://seekingalpha.com/news/4068613-healthcare-dealmakers-see-increased-ma-valuations-in-2024-kpmg?source=feed_sector_healthcare
Feb 19, 2024 - Corporate and private equity dealmakers are anticipating an uptick in healthcare and life sciences M&A activity this year, with higher valuations, according to KPMG survey.
0
Gold Royalty: Market Sees U-Turn, But Better With Lower Prices
https://seekingalpha.com/article/4672250-gold-royalty-market-sees-u-turn-but-better-with-lower-prices?source=feed_all_articles
Feb 21, 2024 - Gold Royalty is poised to gain from the upcoming gold price surge in 2024, with promising financial improvements hinting at profitable growth ahead. See more here.
0
FTI Consulting Q4 Profit Climbs, Tops Estimates; Sees Higher FY24 Results; Stock Up In Pre-market
https://www.rttnews.com/story.aspx?Id=3426693
Feb 22, 2024 - FTI Consulting, Inc. (FCN) reported Thursday that its fourth-quarter net income climbed to $81.6 million from last year's $47.5 million.
0
Traders May See Yesterday's Sell-Off As Buying Opportunity
https://www.rttnews.com/story.aspx?Id=3424551
Feb 14, 2024 - The major U.S. index futures are currently pointing to a higher open on Wednesday, with stocks likely to regain ground following the sell-off seen in the previous session.
0
Novo Nordisk sees launching new obesity drugs before Wegovy patent expires
https://seekingalpha.com/news/4077692-novo-nordisk-sees-launching-new-obesity-drugs-before-wegovy-patent-expires?source=feed_sector_healthcare
Mar 08, 2024 - Novo Nordisk (NVO) reportedly plans to launch its next-generation obesity drugs, Cagrisema and amycretin, ahead of the expiration of its patent for Wegovy. Read more here.
0
Stifel downgrades ALX Oncology to hold, sees evorpacept as fully valued
https://seekingalpha.com/news/4077751-stifel-downgrades-alx-oncology-to-hold-sees-evorpacept-as-fully-valued?source=feed_sector_healthcare
Mar 08, 2024 - Stifel downgraded ALX Oncology (ALXO) to hold, stating it sees the company’s CD47 blocker drug evorpacept as fully valued for the HER2+ gastric cancer opportunity. Read more here.
0
'We're Curating Happiness': See How This Entrepreneur Is Transforming the Wellness Space
https://www.entrepreneur.com/growing-a-business/how-dria-murphy-is-transforming-the-wellness-space/470757
Mar 07, 2024 - The founder of Alise Collective and by dria discusses her entrepreneurial journey and why she's so passionate about making people happier and healthier.
0
Delta CEO sees delay for Boeing 737 MAX 10 deliveries until 2027 - Bloomberg
https://seekingalpha.com/news/4077833-delta-ceo-sees-delay-for-boeing-737-max-10-deliveries-until-2027-bloomberg?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Mar 10, 2024 - Delta Air Lines expects delays in the delivery of Boeing 737 MAX 10 aircraft to as late as 2027 due to safety reviews, CEO Ed Bastian says.
0
U.S. Stocks May See Further Downside Ahead Of Inflation Data
https://www.rttnews.com/story.aspx?Id=3431229
Mar 11, 2024 - Following the notable downturn seen over the course of last Friday's session, stocks are likely to see further downside in early trading on Monday. The major index futures are currently pointing to a lower open for the markets. Uncertainty about the outlook for interest rates may weigh on the markets ahead of the release of key inflation data in the coming days.
0